{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Part+B&page=13",
    "query": {
      "intervention": "Placebo Part B",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 738,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Part+B&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Part+B&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T04:13:01.312Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06615570",
      "title": "A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "VX-973",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2024-09-30",
      "completion_date": "2025-07-21",
      "has_results": false,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06615570"
    },
    {
      "nct_id": "NCT02918266",
      "title": "TAK-071 Scopolamine-Induced Cognitive Impairment Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Scopolamine",
          "type": "DRUG"
        },
        {
          "name": "TAK-071",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine Placebo",
          "type": "DRUG"
        },
        {
          "name": "TAK-071 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2016-11-21",
      "completion_date": "2017-08-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-14",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02918266"
    },
    {
      "nct_id": "NCT02293148",
      "title": "Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "GSK1278863 75 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK1278863 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching GSK1278863",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 61,
      "start_date": "2014-11-17",
      "completion_date": "2015-03-10",
      "has_results": false,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293148"
    },
    {
      "nct_id": "NCT01848340",
      "title": "An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-associated Lipodystrophy Syndrome"
      ],
      "interventions": [
        {
          "name": "GSK1265744B (sodium salt) containing 14C-GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "150 mg GSK1265744B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-04",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848340"
    },
    {
      "nct_id": "NCT01218204",
      "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidaemias",
        "Dyslipidemias"
      ],
      "interventions": [
        {
          "name": "10mg atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "80mg atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "GSK1292263 Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "300mg GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "800mg GSK1292263",
          "type": "DRUG"
        },
        {
          "name": "10mg ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Washout",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 287,
      "start_date": "2010-09-14",
      "completion_date": "2011-06-29",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 21,
      "location_summary": "Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218204"
    },
    {
      "nct_id": "NCT07287033",
      "title": "Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergies"
      ],
      "interventions": [
        {
          "name": "MY006 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "MY006 Mid Dose",
          "type": "DRUG"
        },
        {
          "name": "MY006 High Dose",
          "type": "DRUG"
        },
        {
          "name": "MY006 Selected Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Vehicle)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mabylon AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "12 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2025-12-06",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07287033"
    },
    {
      "nct_id": "NCT05829655",
      "title": "Measuring Acute Drug Demand in Humans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "Drug A (Blinded Drug)",
          "type": "DRUG"
        },
        {
          "name": "Drug B (Blinded Drug)",
          "type": "DRUG"
        },
        {
          "name": "Drug C (Blinded Drug)",
          "type": "DRUG"
        },
        {
          "name": "Drug D (Blinded Drug)",
          "type": "DRUG"
        },
        {
          "name": "Suvorexant (20mg/day)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2023-08-08",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05829655"
    },
    {
      "nct_id": "NCT01463098",
      "title": "A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "E2006 1.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 5.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 10.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 25.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 50.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 100 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Zolpidem 10 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 Matched Placebo or Zolpidem Matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "E2006 Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 122,
      "start_date": "2011-10-05",
      "completion_date": "2012-08-11",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 2,
      "location_summary": "New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01463098"
    },
    {
      "nct_id": "NCT06239116",
      "title": "A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hypothalamic Obesity",
        "Prader-Willi Syndrome",
        "PWS"
      ],
      "interventions": [
        {
          "name": "Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)",
          "type": "DRUG"
        },
        {
          "name": "Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)",
          "type": "DRUG"
        },
        {
          "name": "Part C: RM-718",
          "type": "DRUG"
        },
        {
          "name": "Part D: RM-718",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rhythm Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 111,
      "start_date": "2024-03-05",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06239116"
    },
    {
      "nct_id": "NCT06064006",
      "title": "A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "NNC0487-0111",
          "type": "DRUG"
        },
        {
          "name": "Placebo (NNC0487-0111)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 125,
      "start_date": "2023-09-15",
      "completion_date": "2024-11-27",
      "has_results": false,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-11-21T04:13:01.312Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06064006"
    }
  ]
}